Fig. 2From: Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practiceA TGR (experimental TGR/reference TGR) and (B) TGKR (experimental TGK/reference TGK) distribution. HPD indicates hyperprogressive disease; PD, progressive disease (per RECIST v1.1); SD, stable disease (per RECIST v1.1); PR, partial response (per RECIST v1.1); CR, complete response (per RECIST v1.1)Back to article page